High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol
P Brice, D Simon, R Bouabdallah, C Bélanger, C Haïoun, C Thieblemont, H Tilly, J L Harousseau, C Doyen, C Martin, N Brousse, P H Solal-Céligny, Groupe d'Etude des Lymphomes de l'Adulte (GELA), P Brice, D Simon, R Bouabdallah, C Bélanger, C Haïoun, C Thieblemont, H Tilly, J L Harousseau, C Doyen, C Martin, N Brousse, P H Solal-Céligny, Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Abstract
Background: Among the 566 patients with follicular lymphomas (FL) included in the GELF 86 prospective trials from October 1986 to September 1995, 372 with progressive/relapsing disease were analyzed retrospectively to identify prognostic factors at first relapse.
Patients and methods: For progressive FL, patients received mono- (22%) or polychemotherapy (78%) followed by high-dose therapy (HDT) with ASCT for 83 patients (22%). The median time to progression from initial treatment was 23 months (range 3-102 months) and 24% of documented patients (52 of 217) had histological transformation (HT). Salvage therapy produced an overall response in 64% of patients and the five-year survival from progression was 42%.
Results: For patients who underwent HDT with ASCT compared to standard treatment, five-year freedom from second failure was at 42% vs. 16% (P = 0.0001) and five-year survival was 58% vs. 38% (P = 0.0005), respectively. The benefit of HDT and ASCT remained if we consider only patients less than 65 years (five-year survival at 60% vs. 40%; P = 0.001). Multivariate analysis of parameters significant according to univariate analysis found that no ASCT at first progression, age at relapse > 50 years, progression on-therapy were adversely significant on survival.
Conclusions: HDTwith ASCT compared to standard treatment prolonged remission and survival after first progression of FL patients.
Source: PubMed